{"id":80827,"date":"2023-01-03T07:52:00","date_gmt":"2023-01-03T06:52:00","guid":{"rendered":"https:\/\/enr.today\/?p=80827"},"modified":"2023-01-02T18:53:48","modified_gmt":"2023-01-02T17:53:48","slug":"lemployeur-du-mari-dursula-von-der-leyen-est-independant-de-pfizer","status":"publish","type":"post","link":"https:\/\/europeannewsroom.com\/fr\/lemployeur-du-mari-dursula-von-der-leyen-est-independant-de-pfizer\/","title":{"rendered":"L&#8217;employeur du mari d\u2019Ursula von der Leyen est ind\u00e9pendant de Pfizer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Les contrats pass\u00e9s entre la Commission europ\u00e9enne et Pfizer pour l\u2019achat de vaccins contre le Covid-19 font l\u2019objet de critiques depuis un certain temps. Il&nbsp;<a rel=\"noreferrer noopener\" href=\"https:\/\/archive.ph\/xQA9C\" target=\"_blank\">semblerait<\/a>&nbsp;d\u00e9sormais qu\u2019Heiko von der Leyen, mari de la pr\u00e9sidente de la Commission europ\u00e9enne Ursula von der Leyen, travaillerait dans une entreprise appartenant au groupe Pfizer. Est-ce vrai ?<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\u00c9valuation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Il n\u2019existe aucune preuve selon laquelle Pfizer serait propri\u00e9taire de la soci\u00e9t\u00e9 de biotechnologie Orgenesis, dont le directeur m\u00e9dical est Heiko von der Leyen, le mari d\u2019Ursula von der Leyen.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Faits<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Heiko von der Leyen est bien le mari de l&rsquo;actuelle pr\u00e9sidente de la Commission europ\u00e9enne, Ursula von der Leyen. Ils se sont mari\u00e9s en&nbsp;<a href=\"https:\/\/www.bbc.com\/news\/world-europe-48841980#:~:text=Later%20in%20Germany%20she%20met%20Heiko%20von%20der%20Leyen%2C%20a%20doctor%2C%20at%20medical%20school%20and%20they%20got%20married%20in%201986.\" target=\"_blank\" rel=\"noreferrer noopener\">1986<\/a>. Il est \u00e9galement vrai que ce dernier est le&nbsp;<a href=\"https:\/\/orgenesis.com\/team#:~:text=Heiko%20von%20der,Medical%20Director\" target=\"_blank\" rel=\"noreferrer noopener\">directeur m\u00e9dical<\/a>&nbsp;de l\u2019entreprise de biotechnologie am\u00e9ricaine Orgenesis depuis&nbsp;<a href=\"https:\/\/www.linkedin.com\/in\/heiko-von-der-leyen-62520b154\/?originalSubdomain=de\" target=\"_blank\" rel=\"noreferrer noopener\">septembre 2020<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mais les faits s&rsquo;arr\u00eatent l\u00e0. Rien ne prouve qu&rsquo;Orgenesis soit d\u00e9tenue par Pfizer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Orgenesis est une&nbsp;<a href=\"https:\/\/www.nasdaq.com\/market-activity\/stocks\/orgs\" target=\"_blank\" rel=\"noreferrer noopener\">entreprise cot\u00e9e en bourse<\/a>. Les informations concernant ses&nbsp;<a href=\"https:\/\/money.cnn.com\/quote\/shareholders\/shareholders.html?symb=orgs&amp;subView=institutional#:~:text=top%2010%20owners%20of%20orgenesis%20inc\" target=\"_blank\" rel=\"noreferrer noopener\">actionnaires<\/a>&nbsp;sont donc disponibles publiquement. Quiconque poss\u00e9dant une action de&nbsp;<a href=\"https:\/\/www.investmentfundlawblog.com\/resources\/investments-by-funds\/acquiring-5-publicly-traded-company\/\" target=\"_blank\" rel=\"noreferrer noopener\">plus de 5 %<\/a>&nbsp;dans une entreprise am\u00e9ricaine cot\u00e9e en bourse doit le&nbsp;<a href=\"https:\/\/www.sec.gov\/edgar\/browse\/?CIK=1460602&amp;owner=exclude\" target=\"_blank\" rel=\"noreferrer noopener\">signaler<\/a>&nbsp;\u00e0 la Securities and Exchange Commission.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Il n\u2019y a pas de preuve que Pfizer est actionnaire, m\u00eame s\u2019il n\u2019est pas possible d\u2019exclure l&rsquo;\u00e9ventualit\u00e9 que la compagnie pharmaceutique participe \u00e0 moins de 5 %. Si c\u2019\u00e9tait le cas, Pfizer ne pourrait toutefois pas \u00eatre consid\u00e9r\u00e9e comme propri\u00e9taire et ne pourrait pas intervenir de mani\u00e8re consid\u00e9rable au sein de la direction d\u2019Orgenesis. Sa part serait trop faible pour cela.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Enqu\u00eate en cours<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c0 la mi-octobre, le bureau du procureur g\u00e9n\u00e9ral europ\u00e9en (EPPO) a ouvert une&nbsp;<a href=\"https:\/\/www.eppo.europa.eu\/fr\/node\/359\" target=\"_blank\" rel=\"noreferrer noopener\">enqu\u00eate<\/a>&nbsp;sur l\u2019acquisition de vaccins contre le Covid-19 par l\u2019Union europ\u00e9enne. Le sujet m\u00eame de l\u2019enqu\u00eate reste flou.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Des critiques de longue date ont \u00e9merg\u00e9 sur le myst\u00e8re entourant la signature des contrats de milliards d\u2019euros pass\u00e9s par la Commission europ\u00e9enne aupr\u00e8s de producteurs de vaccins. En novembre 2021, la Commission avait sign\u00e9 des contrats pour un montant total de&nbsp;<a href=\"https:\/\/www.eca.europa.eu\/Lists\/ECADocuments\/INSR22_19\/INSR_EU_COVID_vaccine_procurement_FR.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">71 milliards d\u2019euros<\/a>. On ne sait toutefois pas quelle somme exacte l\u2019entreprise Pfizer a touch\u00e9.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Liens<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.facebook.com\/photo\/?fbid=10228267310416306&amp;set=a.1519402633401\" target=\"_blank\" rel=\"noreferrer noopener\">Publication Facebook 1\/2<\/a>&nbsp;(<a href=\"https:\/\/archive.ph\/xQA9C\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.facebook.com\/photo\/?fbid=10159795852867326&amp;set=a.10150611686907326\" target=\"_blank\" rel=\"noreferrer noopener\">Publication Facebook 2\/2<\/a>&nbsp;(<a href=\"https:\/\/archive.ph\/qX5vw\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.bbc.com\/news\/world-europe-48841980\" target=\"_blank\" rel=\"noreferrer noopener\">Portrait d\u2019Ursula von der Leyen &#8211; BBC<\/a>&nbsp;(<a href=\"https:\/\/web.archive.org\/web\/20221206120522\/https:\/\/www.bbc.com\/news\/world-europe-48841980\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/orgenesis.com\/team\" target=\"_blank\" rel=\"noreferrer noopener\">Membres d&rsquo;Orgenesis<\/a>&nbsp;(<a href=\"https:\/\/web.archive.org\/web\/20221207130807\/https:\/\/orgenesis.com\/team\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.linkedin.com\/in\/heiko-von-der-leyen-62520b154\/?originalSubdomain=de\" target=\"_blank\" rel=\"noreferrer noopener\">Heiko von der Leyen sur LinkedIn<\/a>&nbsp;(<a href=\"https:\/\/archive.vn\/Qla89\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.nasdaq.com\/market-activity\/stocks\/orgs\" target=\"_blank\" rel=\"noreferrer noopener\">Profil d\u2019Orgenesis &#8211; Nasdaq<\/a>&nbsp;(<a href=\"https:\/\/web.archive.org\/web\/20221215155551\/https:\/www.nasdaq.com\/market-activity\/stocks\/orgs\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/money.cnn.com\/quote\/shareholders\/shareholders.html?symb=ORGS&amp;subView=institutional\" target=\"_blank\" rel=\"noreferrer noopener\">Actionnaires d&rsquo;Orgenesis &#8211; CNN Business<\/a>&nbsp;(<a href=\"https:\/\/web.archive.org\/web\/20221115161156\/https:\/\/money.cnn.com\/quote\/shareholders\/shareholders.html?symb=orgs&amp;subView=institutional\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.investmentfundlawblog.com\/resources\/investments-by-funds\/acquiring-5-publicly-traded-company\/\" target=\"_blank\" rel=\"noreferrer noopener\">Loi am\u00e9ricaine sur les actionnaires<\/a>&nbsp;(<a href=\"https:\/\/web.archive.org\/web\/20221103020539\/https:\/\/www.investmentfundlawblog.com\/resources\/investments-by-funds\/acquiring-5-publicly-traded-company\/\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.sec.gov\/edgar\/browse\/?CIK=1460602&amp;owner=exclude\" target=\"_blank\" rel=\"noreferrer noopener\">Orgenesis &#8211; Securities and Exchange Commission<\/a>&nbsp;(<a href=\"https:\/\/archive.vn\/Qyggm\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.eppo.europa.eu\/en\/news\/ongoing-eppo-investigation-acquisition-covid-19-vaccines-eu\" target=\"_blank\" rel=\"noreferrer noopener\">Communiqu\u00e9 de presse EPPO<\/a>&nbsp;(<a href=\"https:\/\/web.archive.org\/web\/20221116103255\/https:\/\/www.eppo.europa.eu\/en\/news\/ongoing-eppo-investigation-acquisition-covid-19-vaccines-eu\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.eca.europa.eu\/Lists\/ECADocuments\/INSR22_19\/INSR_EU_COVID_vaccine_procurement_FR.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Communiqu\u00e9 de presse sur l&rsquo;achat de vaccins<\/a>&nbsp;(<a href=\"https:\/\/web.archive.org\/web\/20221216102257\/https:\/\/www.eca.europa.eu\/Lists\/ECADocuments\/INSR22_19\/INSR_EU_COVID_vaccine_procurement_FR.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">version archiv\u00e9e<\/a>)<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">\u00c0 propos des fact-checks de la dpa<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Vous trouverez d\u2019autres fact-checks de la dpa sur la page&nbsp;<a href=\"https:\/\/dpa-factchecking.com\/\">dpa-factchecking.com<\/a>. Nous vous informons&nbsp;<a href=\"https:\/\/dpa-factchecking.com\/about\/belgium\/#francaise\">ici<\/a>&nbsp;sur les principes de notre travail.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Si vous avez des objections ou des remarques, merci de les envoyer \u00e0 l\u2019adresse&nbsp;<a href=\"mailto:factcheck-belgium@dpa.com\">factcheck-belgium@dpa.com<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Heiko von der Leyen travaille pour l&rsquo;entreprise biotech Orgenesis, qui est distincte du g\u00e9ant pharmaceutique Pfizer.<\/p>\n","protected":false},"author":65,"featured_media":74531,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[829],"tags":[6657,2453,521,6655],"class_list":["post-80827","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fact-check","tag-pharma-2","tag-sante","tag-ue-2","tag-vaccins"],"acf":[],"_links":{"self":[{"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/posts\/80827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/comments?post=80827"}],"version-history":[{"count":0,"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/posts\/80827\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/media\/74531"}],"wp:attachment":[{"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/media?parent=80827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/categories?post=80827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/europeannewsroom.com\/fr\/wp-json\/wp\/v2\/tags?post=80827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}